• Nasdaq staff moved to delist Kyntra Bio shares from the Nasdaq Global Select Market for failing to meet Listing Rule 5450(b).
• Determination letter dated Sept. 30, 2026, cited missed compliance by the Sept. 29, 2026 deadline.
• A hearing request was filed on time, staying any suspension; shares continue trading as KYNB pending a panel decision.
• Panel may grant up to a 180-day extension from the delisting determination; outcome remains uncertain.
• Earlier notice on April 2, 2026 flagged failure to meet the $50 million total assets and total revenue thresholds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-415545), on October 06, 2026, and is solely responsible for the information contained therein.